当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
BREYANZI, lisocabtagene maraleucel
申请企业
Juno Therapeutics, a Celgene Company
药品名称
BREYANZI, lisocabtagene maraleucel
承诺描述
A post-marketing multicenter, prospective, observational study to assess the long-term safety of lisocabtagene maraleucel and the risk of secondary malignancies occurring after treatment with lisocabtagene maraleucel. The study will include at least 1500 adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy; the enrolled patients will be followed for 15 years after the product administration. Final Protocol Submission: February 28, 2021; Study Completion Date: April 30, 2041; Final Report Submission: July 31, 2042.